Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia

NCT ID: NCT07012486

Last Updated: 2025-06-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-30

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is:

• Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA.

Participants will:

* Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months.
* Visit the clinic once every month for checkups and tests.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Androgenetic Alopecia (AGA)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Arm

oral dihydroartemisinin (DHA) combined with topical minoxidil

Group Type ACTIVE_COMPARATOR

Oral DHA + Topical minoxidil 5%

Intervention Type DRUG

DHA 20mg tid po plus daily topical minoxidil 5% for 180 days

Control Arm

topical minoxidil alone

Group Type OTHER

Topical Minoxidil 5%

Intervention Type DRUG

Topical minoxidil 5% daily for 180 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral DHA + Topical minoxidil 5%

DHA 20mg tid po plus daily topical minoxidil 5% for 180 days

Intervention Type DRUG

Topical Minoxidil 5%

Topical minoxidil 5% daily for 180 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinically diagnosed with androgenetic alopecia (AGA)
* No pregnancy plans within the next 6 months

Exclusion Criteria

* Patients who received systemic medications for hair loss within the past 2 months
* Use of topical medication for hair loss within the past 2 weeks
* Pregnancy or lactation
* Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shanghai Zhongshan Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jingjing JIANG, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhongshan Hospital Fudan University

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lujuan GAO, MD, PhD

Role: CONTACT

86-021-64041990

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lujuan, MD, PhD

Role: primary

86-021-64041990

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B2025-112R

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

New Treatment of Alopecia Areata
NCT05594316 COMPLETED NA